NICE issues final word on Celgene, J&J meds; Meda share price puts M&A at a premium;

@FiercePharma: DoJ subpoenas AZ, Medco about four meds. Story | Follow @FiercePharma

> The U.K.'s cost-effectiveness watchdog issued final guidance on multiple myeloma drugs, recommending Celgene's thalidomide for first-line treatment and Johnson & Johnson's Velcade for those who can't take the Celgene med. Piece

> Investors bidding up shares in Meda, the Swedish drugmaker said to be targeted by Valeant Pharmaceuticals for a takeover, may price the company out of the market. Report

> India's Dr Reddy's Laboratories launched its version of Eli Lilly's cancer drug Gemzar in the U.S. News

> Walgreen agreed to pay $140,000 to resolve state and federal claims that it defrauded Medicare and Medicaid by billing multiple times for prescription drugs. News

> The U.S. government will be paying half the nation's healthcare bill by 2020, four percentage points higher than the share in 2010, according to a Health Affairs study. Report

> Pharma wholesaler AmerisourceBergen raised its earnings outlook for the second time this year while posting Q2 profits that beat analyst estimates. Item

> India's Cadila Healthcare bought the German animal health company Bremer Pharma to expand its veterinary drugs business. Story

Biotech News

@FierceBiotech: FDA cites "corrupt" CRO for widespread falsification. News | Follow @FierceBiotech

@JohnCFierce: BMS R&D expenses up 12% in Q2, to $923M; won't be any complaints on that score with net sales rising. | Follow @JohnCFierce

@RyanMFierce: You might have seen this before, Broad Inst. CIO presents a case for injecting video game elements into biotech R&D: Item | Follow @RyanMFierce

@MaureenFierce: E&Y: Biotech jobs on the rise in US, but pressures on business model have increased to extraordinary levels. Report | Follow @MaureenFierce

> Baxter sets up $200M venture arm for early-stage investments. News

> GSK chief sees big shakeout following R&D shutdown. More

> Sanofi lines up a growing slate of late stage drug prospects. Article

> Flush with cash, UK biotech preps new discovery in Oxford. Story

Manufacturing News

> Indianapolis strengthens hold as cold chain hub. Item

> UN conference names Catalent top CMO. Piece

> GSK adds consumer savvy to procurment role. Article

> Russia plots API production conquest. Report

> DB Schenker rolls out RFID temp-monitoring service. Story

> Millipore: single-use plus lean cuts time and materials. News

Vaccine News

> Orelli: BioSante melanoma deal could be better. News

> Sanofi taps Leukocare for vaccine stabilization. Story

> Collins: Universal flu vax will be achieved in 5 years. More

> CEVEC raises $8.5M to commercialize protein, vaccine platform. Article

> Chicken pox vaccine reduces deaths. Report

And Finally... Depression study proves money doesn't make people happy. Report

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.